Guia Covid-19
Imprimir Republish

Data

At least 125 COVID-19 vaccines are in development, with 10 already undergoing clinical trials

  • According to the World Health Organization (WHO), 125 COVID-19 vaccines were in development worldwide by May 27. Ten of them are in the clinical trials phase, during which the vaccine is tested on humans.
  • The most advanced of these 10, currently in trial phase 2b/3, was developed by a group of researchers from the University of Oxford and Pharmaceutical company AstraZeneca, both in the UK.
  • Of the organizations testing vaccines in clinical trials, five are from China, four are from the USA, and one is from the UK.
  • Among the 115 vaccines in the preclinical phase, two are under development in Brazil, one jointly at the Oswaldo Cruz Foundation (FIOCRUZ) and the Butantan Institute, and the other at the University of São Paulo (USP)

 

Vaccines in the clinical trials phase worldwide and in development in Brazil (as of May 27, 2020)

Notes (1) Testing the effects of the product to identify adverse reactions   (2) Whether the expected effect is achieved under controlled conditions   (3) Demonstration that validates a certain theory   (4) dose which produces the desired effects without causing harmful side effects   (5) Ability to achieve the expected effect on a large scale under real-world conditions

Sources  World Health Organization, Draft landscape of Covid-19 candidate vaccines – May 27, 2020. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines. Phases of vaccine development: https://www.ncbi.nlm.nih.gov/books/NBK236428/

Republish